Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Topiramate Glenmark 25mg, 50mg, 100mg and 200mg film-coated tablets {equilateral_black_triangle}

Active Ingredient:
topiramate
Company:  
Glenmark Pharmaceuticals Europe Ltd See contact details
ATC code: 
N03AX11
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Topiramate Annual Risk Awareness Form - Prophylaxis of Migraine

Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form - Prophylaxis of Migraine Topiramate should not be used in patients of childbearing potential unless the conditions of the Pregnancy Prevention Programme are fulfilled. This form outlines the conditions of the topiramate Pregnancy Prevention Programme and when these must be fulfilled. The form should be used to support and record the prescribing decision.
{pdf_link}

Topiramate Annual Risk Awareness Form – Epilepsy

Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form Topiramate should not be used in patients of childbearing potential unless the conditions of the Pregnancy Prevention Programme are fulfilled. This form outlines the condition of the topiramate Pregnancy Prevention Programme and when these must be fulfilled. This form should be used to support and record the prescribing decision.
{pdf_link}

Topiramate Healthcare Professional Guide - Prophylaxis of migraine

{healthcare_pro_orange} For Healthcare Professionals
Topiramate Pregnancy Prevention Programme Information on the risks of topiramate use in women of childbearing potential in the treatment of prophylaxis of migraine
{pdf_link}

Topiramate Healthcare Professional Guide – Epilepsy

{healthcare_pro_orange} For Healthcare Professionals
Topiramate Pregnancy Prevention Programme Information on the risks of topiramate use in girls (of any age) and women of childbearing potential in the treatment of epilepsy.
{pdf_link}

Topiramate Patient Card

Important information for all female patients who could become pregnant
{pdf_link}

Topiramate Patient Guide - Prophylaxis of migraine

Topiramate Pregnancy Prevention Programme Patient Guide: What patients who are able to get pregnant need to know about topiramate
{pdf_link}

Topiramate Patient Guide – Epilepsy

Topiramate Pregnancy Prevention Programme - Patient Guide: What patients who are able to get pregnant need to know about topiramate
{pdf_link}

Topiramate Patient Warning Sticker

{healthcare_pro_orange} For Healthcare Professionals
Sticker for Pharmacies - WARNING FOR WOMEN WHO ARE ABLE TO BECOME PREGNANT

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Glenmark Pharmaceuticals Europe Ltd
Company image
Address
Building 2, Croxley Park, Watford, WD18 8YA
Telephone
+44 (0)1923 202 950
Fax
+44 (0)1923 251137
Medical Information Direct Line
0800 458 0383
E-mail
[email protected]
Stock Availability
+44 (0)1923 202 950
WWW
www.glenmarkpharma.com